Novocure Ltd is a biotechnology company that focuses on developing and commercializing innovative treatments for cancer
The company's primary technology is Tumor Treating Fields (TTFields), a non-invasive therapy that utilizes electric fields to disrupt cancer cell division and inhibit tumor growth. Novocure partners with healthcare providers to bring its advanced therapies to patients suffering from various types of tumors, particularly aggressive forms of cancer. Through ongoing research and collaboration, Novocure aims to improve treatment options and outcomes for patients battling cancer, employing a unique approach that integrates with existing treatment modalities.
Novocure (NASDAQNVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
Novocure (NASDAQNVCR) announced today that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Ashley Cordova, Chief Executive Officer, and William Doyle, Executive Chairman, will speak on behalf of the company and address questions at 9:00 a.m. PST. Ms. Cordova and Mr. Doyle will be joined by Christoph Brackmann, Chief Financial Officer, for one-on-one meetings with investors throughout the conference.
Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQNVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
Novocure (NASDAQNVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
Novocure (NASDAQNVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 21 – 24, Houston, Texas.
Novocure (NASDAQNVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio® for the treatment of adult patients with glioblastoma multiforme (GBM).
Novocure (NASDAQNVCR) announced today that Christoph Brackmann has been appointed as the company’s next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO.
Novocure (NASDAQNVCR) today reported financial results for the third quarter ended September 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
